Abstract
We performed basic and clinical studies on S-1108, a new oral cephalosporin, and obtained the following results.
1) Serum and skin concentrations of S-1006 after single oral doses of S-1108 (75 mg or 150 mg) were determined in patients undergoing skin surgery. The skin/serum concentration ratios were 0.05-0.36 (n=6).
2) S-1108 was given to 10 patients with suppurative skin and soft tissue infections, and the results were excellent in 2 cases and good in 8. No side effects or abnormal laboratory findings were observed.
